Lutetium-(177Lu)-oxodotreotide: Thrombocytopenia.
In: Reactions Weekly, Jg. 2009 (2024-05-30), S. 357-357
serialPeriodical
Zugriff:
In a retrospective study of 205 patients conducted between 2007-2019, a patient with a neuroendocrine tumor developed thrombocytopenia during treatment with lutetium-(177Lu)-oxodotreotide. The specific details of the patient's age, sex, route of administration, dosage, duration of treatment, and outcome were not provided. Thrombocytopenia is a condition characterized by a low platelet count and can be a potential side effect of lutetium-(177Lu)-oxodotreotide treatment. [Extracted from the article]
Titel: |
Lutetium-(177Lu)-oxodotreotide: Thrombocytopenia.
|
---|---|
Zeitschrift: | Reactions Weekly, Jg. 2009 (2024-05-30), S. 357-357 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 0114-9954 (print) |
DOI: | 10.1007/s40278-024-59613-z |
Schlagwort: |
|
Sonstiges: |
|